These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14991758)

  • 1. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy.
    Lee EC; Tenniswood MP
    J Cell Biochem; 2004 Mar; 91(4):662-70. PubMed ID: 14991758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression.
    Knudsen BS; Miranti CK
    J Cell Biochem; 2006 Oct; 99(2):345-61. PubMed ID: 16676354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
    Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
    Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
    Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of androgen receptor in prostate cancer.
    Linja MJ; Visakorpi T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of prostate cancer. Part 3: metastatic disease.
    Shah J; Khaksar SJ; Sooriakumaran P
    Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z; Wenlu S
    Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
    Foley R; Marignol L; Keane JP; Lynch TH; Hollywood D
    Prostate; 2011 Apr; 71(5):550-7. PubMed ID: 20945429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
    Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.